Key result
Breast cancer chemotherapy linked to ~64% lower cardiac autonomic reactivity and HRV versus healthy controls.
Why the study?
Cardiac autonomic dysfunction affects quality of life and survival in breast cancer patients, making thorough assessment of cardiovascular autonomic functions crucial to monitor prognosis and chemotherapy side effects.
Does breast cancer chemotherapy cause cardiac autonomic dysfunction in breast cancer patients?
Population
25 breast cancer patients (stage I-III, age 30-65 years) on chemotherapy and 25 healthy female volunteers
Comparison
Histologically proven stage I-III breast cancer patients after three chemotherapy cycles vs healthy controls
Design
Case-control study
Authors
Loading...
May warrant autonomic monitoring in breast cancer chemotherapy; leaves open causality versus disease effects.
Case-Control (n=50)
No
Does breast cancer chemotherapy cause cardiac autonomic dysfunction in breast cancer patients?
Absolute Event Rate: 8% vs 22%
p-value: p=0.001
Breast cancer patients undergoing chemotherapy exhibit significant cardiac autonomic dysfunction compared to healthy controls, highlighting the need for autonomic monitoring in cardio-oncology.
Khandelwal et al. (2023) conducted a case-control in Breast cancer (n=50). Chemotherapy vs. Healthy controls was evaluated on Change in heart rate (∆HR) during deep breathing test (bpm) (p=0.001). Breast cancer patients who received three cycles of chemotherapy exhibited significantly reduced cardiac autonomic reactivity and heart rate variability compared to healthy controls.